Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Eli Lilly's comprehensive Phase 3 program includes seven additional trials evaluating retatrutide across multiple indications: Expected 2026 Readouts TRIUMPH-1: Complete (May 2026) 28.3% average weight loss in 2,339 patients
Sources Li, Z., Wang, Y., Xu, Q., Ma, J., Li, X., Yan, J., Tian, Y., Wen, Y., Chen, T
Instead of merely addressing symptoms, peptides support the underlying biological processes disrupted during menopause
The risk is likely lower for patients who are already at or near their goal weight and switching for maintenance purposes, but nutritional vigilance remains essential
This dual approach makes it easier to lose weight steadily, avoid plateaus, and maintain motivation throughout the process
Because our program is backed by science and designed by experts, your unique treatment plan aims to foster healthy, sustainable weight loss
US$ 26.32
US$ 27.92
US$ 23.06
US$ 28.69
US$ 22.43
